Multicentric, Parallel, Controlled, Randomized, Single-blind Clinical Evaluation of New Low Sodium Peritoneal Dialysis Solution on Patients With Hypertension Treated With Continuous Ambulatory or Automated Peritoneal Dialysis
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 140
- 试验地点
- 28
- 主要终点
- The primary criterion is the ambulatory 24 h mean systolic blood pressure measurement and drug doses management after 2 months of treatment compared to Baseline.
研究概览
简要总结
The aim of this study is to assess the superiority of the new low sodium peritoneal dialysis (PD) solution PDsol 12 in comparison with a conventional, already marketed solution, Gambrosol trio 40, in the treatment of the hypertensive peritoneal dialysis patients with aim to decrease hypertension and to improve the sodium/water balance.
详细描述
Hypertension as well as sodium and water retention are common in end-stage renal disease patients on peritoneal dialysis and expose patients to left ventricular hypertrophy and increase cardiovascular mortality.
Moreover the poor control of dry weight and sodium/water balance results in increased morbidity. A previous low sodium study and computer simulations show that sodium removal can be improved with a low sodium fluid, which allows achieving a negative sodium balance without altering water balance.
The aim of this study is to assess whether treatment with one low sodium bag can substitute for one isotonic glucose bag every day in order to reduce the blood pressure and/or medication for hypertension, defined as the primary endpoint.
In order to evaluate the main criteria, blood pressure, a 24hours Ambulatory Blood Pressure Monitoring (ABPM) will be performed twice during the study, at Baseline and at 8 weeks of treatment, according to the EMEA guidance recommendations for anti-hypertensive treatments. In addition, the self measurement of blood pressure will be performed by patients at home during three consecutive days before each visit as well as in case of symptoms of hypotension.
The study is designed in three periods:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronic renal failure
- •Stable patients on PD treatment
- •Treatment at the study site for at least three months
- •Treated in a CAPD program with a minimum of 3 bag exchanges with 6 or 7 days per week including at least one with duration of 4-6 hours, and at least one low strength bag per day, or in an APD program with at least one daytime exchange with duration of 4-6 hours using one low strength bag
- •Hypertensive patients with high blood pressure at inclusion visit (Office SBP ≥ 140 and/or DBP ≥ 90 mmHg) or hypertensive patients receiving anti hypertensive medication including diuretics, disregarded blood pressure values
- •Patients aged 18 years or more
- •Written consent to participate in the study (informed consent)
- •Able to use a three-compartment bag
- •Life expectancy and expected technical survival ≥ 9 months
排除标准
- •Low blood pressure (Office sitting SBP ≤ 120 mmHg and confirmed by ABPM < or = to 105 mean 24h SBP)
- •Orthostatic hypotension defined as Systolic OBP with a drop of > 20mmHg and symptomatic after standing for at least 1 minute
- •Natremia < 130 mmol/l, after two consecutive measurements
- •Chronic arrhythmia
- •Pregnancy or lactation
- •Participation in other studies during the study period which may affect the outcome of the present study
- •Peritonitis within one month prior to the study start
- •Exit site and /or tunnel infection
- •Patients unable to tolerate 2 L bag exchanges
- •Patients on non-compatible PD system
研究组 & 干预措施
PDsol 12
Treatment with a peritoneal dialysis solution containing a low concentration of sodium.
干预措施: Solution for Peritoneal Dialysis (Drug)
Gambrosol trio 40
Treatment with the peritoneal dialysis solution Gambrosol trio 40 isotonic bag (1.5%)
干预措施: Solution for Peritoneal Dialysis (Drug)
结局指标
主要结局
The primary criterion is the ambulatory 24 h mean systolic blood pressure measurement and drug doses management after 2 months of treatment compared to Baseline.
时间窗: At the beginning and after 8 weeks of treatment
次要结局
- Measurement of Residual Renal Function(At the beginning, at two and six months of treatment)
- Follow-up of frequency of hyponatremia, of AE and SAE(During whole period of the study)
- Measurement of 24hours peritoneal clearance(At the beginning and at 2 months of treatment)
- Office systolic and diastolic blood pressure measurement at month 2 and 6 versus T0(At the beginning, at two and six months of treatment)
- Office systolic and diastolic blood pressure measurement during follow up period(End of treatment, follow-up period)
- Assessment of changes in sodium removal(At the beginning and at two months of treatment)
- Assessment of decrease in total body water (extra and intra cellular water)and of the body weigh changes(At the beginning, at two and at six months of treatment)